{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:45:25Z","timestamp":1791841525270,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210227"],"award-info":[{"award-number":["RP210227"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA281727"],"award-info":[{"award-number":["R01CA281727"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA283402"],"award-info":[{"award-number":["R01CA283402"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA282282"],"award-info":[{"award-number":["R01CA282282"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008527","name":"Baylor College of Medicine Dan L Duncan Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008527","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.isci.2026.116184","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:00:45Z","timestamp":1780434045000},"page":"116184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers"],"prefix":"10.1016","volume":"29","author":[{"given":"Elavarasan","family":"Subramani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Pili\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Slack-Tidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"Viscuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghong","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirukumaran","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny J.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine B.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amado J.","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Soundararajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrajee","family":"Piyarathna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanta","family":"Putluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagireddy","family":"Putluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sreekumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Zoubeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Lorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreyashi","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0713-471X","authenticated-orcid":false,"given":"Daniel E.","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116184_bib1","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1158\/1078-0432.CCR-23-3740","article-title":"A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"30","author":"Aparicio","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","article-title":"Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.116184_bib3","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib4","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib5","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.116184_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/2159-8290.CD-16-1174","article-title":"Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer","volume":"7","author":"Zou","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.116184_bib8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.116184_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005070","article-title":"Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer","volume":"7","author":"Li","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.isci.2026.116184_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116184_bib11","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","article-title":"PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers","volume":"25","author":"Pili\u00e9","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib12","doi-asserted-by":"crossref","first-page":"28575","DOI":"10.18632\/oncotarget.15338","article-title":"Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer","volume":"8","author":"Allison Stewart","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.116184_bib13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.116184_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41540-017-0011-6","article-title":"Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm","volume":"3","author":"McGrail","year":"2017","journal-title":"npj Syst. Biol. Appl."},{"key":"10.1016\/j.isci.2026.116184_bib15","doi-asserted-by":"crossref","first-page":"47154","DOI":"10.18632\/oncotarget.17005","article-title":"Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1\/2 mutated patients with advanced ovarian cancer","volume":"8","author":"Rafii","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.116184_bib57","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/cancers14133233","article-title":"Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components","volume":"14","author":"Soundararajan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.116184_bib58","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.isci.2026.116184_bib16","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/molecules28052150","article-title":"Bench-to-Bedside Studies of Arginine Deprivation in Cancer","volume":"28","author":"Field","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.isci.2026.116184_bib17","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-18-4140","article-title":"MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion","volume":"25","author":"Chalishazar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.116184_bib19","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41416-020-01230-8","article-title":"Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies","volume":"124","author":"Yao","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.116184_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1186\/1471-2407-14-621","article-title":"Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy","volume":"14","author":"McAlpine","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.isci.2026.116184_bib21","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.18632\/oncotarget.3370","article-title":"Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin","volume":"6","author":"Savaraj","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.116184_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.116184_bib23","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib24","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1158\/1078-0432.CCR-20-0479","article-title":"The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development","volume":"26","author":"Palanisamy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib25","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1158\/1078-0432.CCR-23-2438","article-title":"Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series","volume":"30","author":"Anselmino","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/pros.21301","article-title":"Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles","volume":"71","author":"Aparicio","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.isci.2026.116184_bib27","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/ijc.25202","article-title":"Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer","volume":"126","author":"Delage","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2026.116184_bib28","doi-asserted-by":"crossref","first-page":"82658","DOI":"10.18632\/oncotarget.12308","article-title":"Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1alpha, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation","volume":"7","author":"Long","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.116184_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146827","article-title":"Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer","volume":"6","author":"Brennen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.116184_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tibs.2015.01.004","article-title":"Famine versus feast: understanding the metabolism of tumors in vivo","volume":"40","author":"Mayers","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.isci.2026.116184_bib31","first-page":"20.5.1","article-title":"The TRAMP mouse as a model for prostate cancer","volume":"20","author":"Hurwitz","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.isci.2026.116184_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102804","article-title":"Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer","volume":"12","author":"Haughey","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.116184_bib33","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/0008-5472.CAN-08-3157","article-title":"Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30591-7","article-title":"Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes","volume":"8","author":"Alexandrou","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.116184_bib35","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.ccell.2023.09.012","article-title":"Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring","volume":"41","author":"Colbert","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116184_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.116184_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.116184_bib38","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1476-5381.2009.00278.x","article-title":"Recent advances in arginine metabolism: roles and regulation of the arginases","volume":"157","author":"Morris","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2026.116184_bib39","article-title":"Arginine Signaling and Cancer Metabolism","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.116184_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq3802","article-title":"Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers","volume":"11","author":"Mao","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.isci.2026.116184_bib41","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116184_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cell.2016.02.035","article-title":"The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway","volume":"165","author":"Chantranupong","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116184_bib43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature14107","article-title":"SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1","volume":"519","author":"Rebsamen","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116184_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1126\/science.1257132","article-title":"Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1","volume":"347","author":"Wang","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.116184_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216931","article-title":"Unveiling the significance of inducible nitric oxide synthase: Its impact on cancer progression and clinical implications","volume":"592","author":"Chen","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2026.116184_bib46","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.trecan.2025.05.002","article-title":"Novel metabolic routes to cancer immune evasion","volume":"11","author":"Jaa","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2026.116184_bib47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jso.24490","article-title":"Arginine-Dual roles as an onconutrient and immunonutrient","volume":"115","author":"Albaugh","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.isci.2026.116184_bib48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fonc.2018.00067","article-title":"Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy","volume":"8","author":"Kim","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.116184_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004089","article-title":"Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy","volume":"10","author":"Augustin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.116184_bib50","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116184_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2026.01.011","article-title":"Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis","author":"Pedrani","year":"2026","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.isci.2026.116184_bib52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/sim.4780140404","article-title":"Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes","volume":"14","author":"Thall","year":"1995","journal-title":"Stat. Med."},{"key":"10.1016\/j.isci.2026.116184_bib53","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2016.10.007","article-title":"Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis","volume":"30","author":"Kettner","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116184_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz019","article-title":"Methionine-Homocysteine Pathway in African-American Prostate Cancer","volume":"3","author":"Gohlke","year":"2019","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.isci.2026.116184_bib55","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/0008-5472.CAN-23-0555","article-title":"Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity","volume":"84","author":"Awad","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116184_bib56","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226015592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226015592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:56:01Z","timestamp":1791838561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226015592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2589004226015592"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116184","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116184"}}